Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC ACS Applied Electronic Materials Pub Date : 2024-07-01 DOI:10.1016/j.cllc.2024.04.003

Amit A. Kulkarni , Cassandra Hennessy , Grace Wilson , Vidhyalakshmi Ramesh , Clara Hwang , Joy Awosika , Ziad Bakouny , Hina Khan , Diana Vilar-Compte , Rana McKay , Chinmay Jani , Lisa Weissmann , Elizabeth Griffiths , Gerald Batist , Nathaniel Bouganim , Blanche Mavromatis , Babar Bashir , Ryan H. Nguyen , Jonathan W. Riess , Matthew Puc , Narjust Florez

{"title":"Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis","authors":"Amit A. Kulkarni , Cassandra Hennessy , Grace Wilson , Vidhyalakshmi Ramesh , Clara Hwang , Joy Awosika , Ziad Bakouny , Hina Khan , Diana Vilar-Compte , Rana McKay , Chinmay Jani , Lisa Weissmann , Elizabeth Griffiths , Gerald Batist , Nathaniel Bouganim , Blanche Mavromatis , Babar Bashir , Ryan H. Nguyen , Jonathan W. Riess , Matthew Puc , Narjust Florez","doi":"10.1016/j.cllc.2024.04.003","DOIUrl":null,"url":null,"abstract":"<div><ul><li>•Patients with thoracic cancers and COVID-19 have high mortality and morbidity.</li><li>•Systematic data evaluating the impact of recent anti-cancer therapies on COVID-19 outcomes in patients with thoracic cancers are limited.</li><li>•We analyzed clinical data from patients with thoracic cancers and COVID-19 (N=927) to systematically evaluate the impact of recent anti-cancer therapies on the clinical outcomes of COVID-19 from the COVID-19 and Cancer Consortium (CCC19).</li><li>•As opposed to immunotherapy or targeted therapy, recent (<3 months prior to COVID-19 diagnosis) cytotoxic chemotherapy exposure was significantly associated with COVID-19 severity.</li><li>•None of the other systemic therapies or treatment modalities were significantly associated with 30-day all-cause mortality.</li><li>•Baseline steroid use of 10 mg or more of prednisone equivalent was not associated COVID-19 severity and 30-day all-cause mortality.</li></ul></div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525730424000445","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}

引用次数: 0

Abstract

•
Patients with thoracic cancers and COVID-19 have high mortality and morbidity.
•
Systematic data evaluating the impact of recent anti-cancer therapies on COVID-19 outcomes in patients with thoracic cancers are limited.
•
We analyzed clinical data from patients with thoracic cancers and COVID-19 (N=927) to systematically evaluate the impact of recent anti-cancer therapies on the clinical outcomes of COVID-19 from the COVID-19 and Cancer Consortium (CCC19).
•
As opposed to immunotherapy or targeted therapy, recent (<3 months prior to COVID-19 diagnosis) cytotoxic chemotherapy exposure was significantly associated with COVID-19 severity.
•
None of the other systemic therapies or treatment modalities were significantly associated with 30-day all-cause mortality.
•
Baseline steroid use of 10 mg or more of prednisone equivalent was not associated COVID-19 severity and 30-day all-cause mortality.